Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

T cell stemness and dysfunction in tumors are triggered by a common mechanism.

Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP.

Science. 2019 Mar 29;363(6434). pii: eaau0135. doi: 10.1126/science.aau0135.

PMID:
30923193
2.

The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells.

Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, Restifo NP, Samelson LE.

Sci Rep. 2018 Mar 28;8(1):5336. doi: 10.1038/s41598-018-23549-2.

3.

Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.

Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, Henning AN, Good ML, Bosch-Marce M, Maeda T, Liu C, Abdullaev Z, Pack S, Palmer DC, Stroncek DF, Ito F, Flomerfelt FA, Kruhlak MJ, Restifo NP.

Cell Rep. 2018 Mar 20;22(12):3175-3190. doi: 10.1016/j.celrep.2018.02.087.

4.

Can Collateral Behavior Account for Transitions in the Stimulus Control of Speech?

Palmer DC.

Anal Verbal Behav. 2017 Sep 18;33(2):205-211. doi: 10.1007/s40616-017-0086-6. eCollection 2017 Oct.

5.

Jack Michael's Musings on the 60th Anniversary of Skinner's Verbal Behavior.

Esch BE, Esch JW, Palmer DC.

Anal Verbal Behav. 2017 Apr 4;33(2):269-274. doi: 10.1007/s40616-017-0078-6. eCollection 2017 Oct.

6.

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP.

Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14.

7.

On Intraverbal Control and the Definition of the Intraverbal.

Palmer DC.

Anal Verbal Behav. 2016 Sep 12;32(2):96-106. doi: 10.1007/s40616-016-0061-7. eCollection 2016 Oct.

8.

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.

Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, Palmer DC, Phan AT, Goulding J, Gattinoni L, Goldrath AW, Belkaid Y, Restifo NP.

Cell. 2016 Aug 25;166(5):1117-1131.e14. doi: 10.1016/j.cell.2016.07.032.

9.

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.

Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, Fabozzi G, Shih HY, Kanno Y, Muto A, Zhu J, Gattinoni L, O'Shea JJ, Okkenhaug K, Igarashi K, Leonard WJ, Restifo NP.

Nat Immunol. 2016 Jul;17(7):851-860. doi: 10.1038/ni.3441. Epub 2016 May 9.

10.

The transcription factor BACH2 promotes tumor immunosuppression.

Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM, Yu Z, Mehta G, Liu H, Jin P, Ji Y, Palmer DC, Pan JH, Chichura A, Crompton JG, Patel SJ, Stroncek D, Wang E, Marincola FM, Okkenhaug K, Gattinoni L, Restifo NP.

J Clin Invest. 2016 Feb;126(2):599-604. doi: 10.1172/JCI82884. Epub 2016 Jan 5.

11.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, Rao M, Keyvanfar K, Schrump DS, Wang E, Marincola FM, Gattinoni L, Leonard WJ, Muranski P, Finkel T, Restifo NP.

Cell Metab. 2016 Jan 12;23(1):63-76. doi: 10.1016/j.cmet.2015.11.002. Epub 2015 Dec 8.

12.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.

J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.

13.

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.

Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP.

J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2.

14.

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Rodriguez-Peña AB, Gomez-Rodriguez J, Kortum RL, Palmer DC, Yu Z, Guittard GC, Wohlfert EA, Silver PB, Misplon JA, Sommers CL, Feigenbaum L, Epstein SL, Caspi RR, Belkaid Y, Restifo NP, Samelson LE, Balagopalan L.

Gene Ther. 2015 Oct;22(10):781-92. doi: 10.1038/gt.2015.48. Epub 2015 Jun 18.

15.

Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape.

Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP.

Cell Mol Immunol. 2016 Jul;13(4):502-13. doi: 10.1038/cmi.2015.32. Epub 2015 Apr 27.

16.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, Telford WG, Palmer DC, Franco Z, Sukumar M, Roychoudhuri R, Clever D, Klebanoff CA, Surh CD, Waldmann TA, Restifo NP, Gattinoni L.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):476-81. doi: 10.1073/pnas.1422916112. Epub 2014 Dec 29.

17.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.

Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.

18.

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP.

Cancer Immunol Res. 2015 Jan;3(1):37-47. doi: 10.1158/2326-6066.CIR-14-0122. Epub 2014 Oct 30.

19.

Acoustic phonons and negative thermal expansion in MOF-5.

Rimmer LH, Dove MT, Goodwin AL, Palmer DC.

Phys Chem Chem Phys. 2014 Oct 21;16(39):21144-52. doi: 10.1039/c4cp01701c. Epub 2014 Aug 7.

PMID:
25100172
20.

Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.

Ji Y, Abrams N, Zhu W, Salinas E, Yu Z, Palmer DC, Jailwala P, Franco Z, Roychoudhuri R, Stahlberg E, Gattinoni L, Restifo NP.

PLoS One. 2014 May 14;9(5):e96650. doi: 10.1371/journal.pone.0096650. eCollection 2014.

21.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.

J Clin Invest. 2013 Oct;123(10):4479-88. doi: 10.1172/JCI69589. Epub 2013 Sep 16.

22.
23.

Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.

Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.

J Exp Med. 2013 Sep 23;210(10):1961-76. doi: 10.1084/jem.20122508. Epub 2013 Sep 2.

24.

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.

Immunity. 2013 Apr 18;38(4):742-53. doi: 10.1016/j.immuni.2012.12.006.

25.

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP.

Mol Ther. 2013 Jul;21(7):1369-77. doi: 10.1038/mt.2013.58. Epub 2013 Apr 9.

26.

Is variability an operant?: introductory remarks.

Palmer DC.

Behav Anal. 2012 Fall;35(2):209-11. No abstract available.

27.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.

Gene Ther. 2013 May;20(5):575-80. doi: 10.1038/gt.2012.75. Epub 2012 Sep 13.

28.

The role of atomic repertoires in complex behavior.

Palmer DC.

Behav Anal. 2012 Spring;35(1):59-73.

29.

Consideration of Private Events is Required in a Comprehensive Science of Behavior.

Palmer DC.

Behav Anal. 2011 Fall;34(2):201-7. No abstract available.

30.

Th17 cells are long lived and retain a stem cell-like molecular signature.

Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.

Immunity. 2011 Dec 23;35(6):972-85. doi: 10.1016/j.immuni.2011.09.019. Epub 2011 Dec 15.

31.

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.

Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.

Nat Immunol. 2011 Nov 6;12(12):1230-7. doi: 10.1038/ni.2153.

32.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7.

33.

The multiple control of verbal behavior.

Michael J, Palmer DC, Sundberg ML.

Anal Verbal Behav. 2011;27(1):3-22.

34.

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

Ha SP, Klemen ND, Kinnebrew GH, Brandmaier AG, Marsh J, Hangoc G, Palmer DC, Restifo NP, Cornetta K, Broxmeyer HE, Touloukian CE.

J Clin Invest. 2010 Dec;120(12):4273-88. doi: 10.1172/JCI43274. Epub 2010 Nov 15.

35.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.

Blood. 2011 Jan 20;117(3):808-14. doi: 10.1182/blood-2010-05-286286. Epub 2010 Oct 22.

36.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP.

Cancer Res. 2010 Sep 1;70(17):6725-34. doi: 10.1158/0008-5472.CAN-10-0735. Epub 2010 Jul 20.

37.
38.

IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells.

Bolinger B, Engeler D, Krebs P, Miller S, Firner S, Hoffmann M, Palmer DC, Restifo NP, Tian Y, Clavien PA, Ludewig B.

Eur J Immunol. 2010 Mar;40(3):733-43. doi: 10.1002/eji.200939706.

39.

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.

J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc.

40.

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Palmer DC, Restifo NP.

Trends Immunol. 2009 Dec;30(12):592-602. doi: 10.1016/j.it.2009.09.009. Epub 2009 Oct 30. Review.

41.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

42.

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP.

Blood. 2009 Aug 27;114(9):1776-83. doi: 10.1182/blood-2008-12-192419. Epub 2009 Jun 26.

43.

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.

Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.

Nat Med. 2009 Jul;15(7):808-13. doi: 10.1038/nm.1982. Epub 2009 Jun 14.

44.

Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Tewalt EF, Grant JM, Granger EL, Palmer DC, Heuss ND, Gregerson DS, Restifo NP, Norbury CC.

PLoS Pathog. 2009 May;5(5):e1000457. doi: 10.1371/journal.ppat.1000457. Epub 2009 May 29.

45.

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.

Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB.

Ophthalmology. 2009 May;116(5):981-989.e1. doi: 10.1016/j.ophtha.2008.12.004.

46.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.

Blood. 2008 Dec 1;112(12):4746-54. doi: 10.1182/blood-2008-07-169797. Epub 2008 Sep 17.

47.

TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation.

Ahn S, Lee G, Yang SJ, Lee D, Lee S, Shin HS, Kim MC, Lee KN, Palmer DC, Theoret MR, Jenkinson EJ, Anderson G, Restifo NP, Kim MG.

PLoS Biol. 2008 Aug 5;6(8):e191. doi: 10.1371/journal.pbio.0060191.

48.

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.

Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6. doi: 10.1073/pnas.0710929105. Epub 2008 Jun 3.

49.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

50.

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP.

Blood. 2008 Jun 1;111(11):5326-33. doi: 10.1182/blood-2007-09-113050. Epub 2008 Feb 14.

Supplemental Content

Loading ...
Support Center